What are the latest advances in 22q13 deletion / Phelan-McDermid Syndrome?

TL;DR: Research into 22q13 deletion, also known as Phelan-McDermid Syndrome (PMS), is currently focused on precision medicine, specifically targeting the SHANK3 gene to address underlying neurological development. While there is no cure, recent breakthroughs include the exploration of IGF-1 analogs and other pharmacological interventions aimed at improving synaptic function and communication in individuals with the condition.

What is the current focus of research for Phelan-McDermid Syndrome?

The primary research focus for 22q13 deletion revolves around the SHANK3 gene, which is critical for synaptic formation and neuronal communication. Because 22q13 deletion leads to a haploinsufficiency of this gene, researchers are investigating ways to restore or bypass its function. Current efforts are largely centered on translational research that bridges the gap between laboratory models and human clinical application, aiming to treat the core neurodevelopmental symptoms of Phelan-McDermid Syndrome.

Are there new pharmacological treatments or clinical trials?

Several clinical trials have recently investigated potential therapies for Phelan-McDermid Syndrome. These studies often focus on modulating pathways affected by SHANK3 deficiency. Key areas of investigation include:

• IGF-1 (Insulin-like Growth Factor 1) Analogues: Studies have explored whether these can improve synaptic plasticity and social behaviors.


• Glutamatergic Modulators: Research is examining agents that influence glutamate receptors, which are often dysregulated in individuals with 22q13 deletion.


• Gene Therapy Perspectives: While still in early pre-clinical stages, gene replacement strategies aim to deliver a functional copy of the SHANK3 gene to affected neurons.

How are diagnostic tools and biomarkers evolving?

Precision medicine for Phelan-McDermid Syndrome is being supported by the development of more sensitive diagnostic biomarkers. Researchers are increasingly using induced pluripotent stem cells (iPSCs) derived from patients to create "disease-in-a-dish" models. These models allow scientists to test thousands of compounds in a controlled environment, significantly accelerating the discovery phase of potential treatments for 22q13 deletion. Furthermore, digital phenotyping and standardized clinical outcome assessments are helping researchers better measure the efficacy of interventions in clinical settings.

Who is leading the research efforts?

Global collaboration is a hallmark of Phelan-McDermid Syndrome research. Leading institutions and organizations include the Phelan-McDermid Syndrome Foundation (PMSF), which maintains an international patient registry, and the Simons Searchlight project. These organizations work alongside academic medical centers to pool data from the 35 members currently active in the DiseaseMaps.org community and thousands of others globally to ensure that clinical trials are well-informed by real-world patient data.

Next steps

• Visit ClinicalTrials.gov and search for "Phelan-McDermid Syndrome" to see currently recruiting studies.


• Register with the Phelan-McDermid Syndrome Foundation to stay informed about the latest research updates and clinical trial opportunities.


• Consult with a geneticist or neurologist to discuss how recent clinical trial findings might be relevant to your specific 22q13 deletion variant.


• Consider participating in natural history studies, which provide essential data for future drug development.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always consult with your physician or a qualified healthcare provider regarding any medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD)


• Phelan-McDermid Syndrome Foundation (PMSF) - Research and Clinical Trials Portal


• Orphanet: Phelan-McDermid syndrome (ORPHA:2767)


• OMIM: Phelan-McDermid Syndrome (Entry #606232)